Rainbow BioSciences
Develops magnetic levitation-based 3D bioprinting systems for high-throughput pharmaceutical drug screening and regenerative medicine.
- CEO / Founder
- Kimberly Palmer
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Venture Round
- Key Investors
- Rainbow Coral Corp
Technology & Products
Key Products
BiO Assay; Bio-Assembler; NanoShuttle
Technological Advantage
Rapid tissue formation (15 minutes to hours) and label-free quantitative shrinkage measurement for high-throughput drug toxicity testing.
Differentiation
Value Proposition
Reduces drug development costs and improves efficacy by replacing 2D assays and animal testing with high-throughput 3D tissue models printed in minutes.
How They Differentiate
Magnetic levitation technology enables faster tissue assembly (minutes vs days) and scaffold-free 3D structures compared to extrusion-based bioprinting.
Market & Competition
Target Customers
Pharmaceutical companies and medical research institutions
Industry Verticals
Pharmaceutical; Biotechnology; Medical Research
Competitors
Organovo
Growth & Milestones
Growth Metrics
Printing speed: 15 minutes to a few hours; 1mm tumor tissue generated in 24 hours; 3D bioprinting market projected to reach $800M in 2016.
Major Milestones
2012: Formed as subsidiary of Rainbow Coral Corp; 2012: Strategic joint venture with Nano3D Biosciences; Launched BiO Assay commercially; Demonstrated 3D breast tumor tissue printing for drug testing
Notable Customers
AstraZeneca